Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $5.2 million.

  • Nurix Therapeutics' Change in Account Payables rose 103.93% to $2.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $3.9 million, marking a year-over-year increase of 72.82%. This contributed to the annual value of $5.2 million for FY2024, which is 222.74% up from last year.
  • Nurix Therapeutics' Change in Account Payables amounted to $5.2 million in FY2024, which was up 222.74% from $1.6 million recorded in FY2023.
  • Nurix Therapeutics' Change in Account Payables' 5-year high stood at $5.2 million during FY2024, with a 5-year trough of $85,000 in FY2022.
  • Its 3-year average for Change in Account Payables is $2.3 million, with a median of $1.6 million in 2023.
  • In the last 5 years, Nurix Therapeutics' Change in Account Payables slumped by 94.65% in 2022 and then soared by 1,798.82% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Change in Account Payables (Yearly) stood at $1.2 million in 2020, then increased by 28.77% to $1.6 million in 2021, then slumped by 94.65% to $85,000 in 2022, then skyrocketed by 1,798.82% to $1.6 million in 2023, then surged by 222.74% to $5.2 million in 2024.